E12. Predictors of resistance to hormonal therapy in breast cancer

European Journal of Cancer, Supplement

Volumn 2, Issue 9 SPEC. ISS., 2004, Pages 43-44

  Dowsett, Mitch ^a   Martin, Lesley Anne ^a   Johnston, Stephen ^a   Smith, Ian E ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; PROGESTERONE RECEPTOR; TAMOXIFEN;

BREAST CANCER; CANCER HORMONE THERAPY; CANCER PATIENT; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE MARKER; DRUG RESISTANCE; HUMAN; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT OUTCOME; TUMOR GROWTH; TUMOR REGRESSION;

EID: 9744285145     PISSN: 13596349     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejcsup.2004.08.011     Document Type: Conference Paper

References (5)

1. Speirs V, Malone C, Walton DS, Kerin MJ, Atkin SL. Increased expression of estrogen receptor beta mRNA in tamoxifen-resistant breast cancer patients. Cancer Res. 1999, 59, 5421-5424.
2. Johnston SR, Saccani-Jotti G, Smith IE, et al. Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer. Cancer Res. 1995, 55, 3331-3338.
3. Ellis MJ, Coop A, Singh B, et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol. 2001, 19, 3808-3816.
4. Smith IE, Dowsett M, Ebbs, SR et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen or both in combination: the IMPACT multicentre double-blind randomised trial. J Clin Oncol, in press.
5. Martin LA, Farmer I, Johnston SR, Ali S, Marshall C, Dowsett M. Enhanced estrogen receptor (ER) alpha, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation. J Biol Chem. 2003, 278, 30458-30468.